This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): NCX-1000
Description: NCX-1000 is a chemical entity obtained by adding an Nitric oxide-releasing moiety to ursodeoxycholic acid, a compound that is selectively metabolized by hepatocytes.
Deal Structure: In May 2002, NicOx S.A. and Axcan Pharma announced the signing of a co-development and license agreement for NCX 1000 for the treatment of chronic liver diseases including portal hypertension and Hepatitis C.
Under the terms of this agreement Nicox grants Axcan an exclusive license to commercialise NCX 1000 in Canada and Poland as well as an option to the same exclusive rights for the United States market. The United States option is to be exercised on completion of proof of concept in Phase II clinical development. NicOx retains rights in the rest of the world including the Far East and Europe with the exception of France where Axcan is granted co-exclusive rights. Axcan and NicOx will share the cost of the future development of NCX 1000 jointly through the completion of Phase II clinical studies. Axcan will thereafter conduct the required Phase III clinical studies and be responsible for regulatory filings in the exclusive licensed territories. Axcan will make licence, option...See full deal structure in Biomedtracker
NCX 1000 News
Additional information available to subscribers only: